News from spinifex pharmaceuticals A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 03, 2014, 04:00 ET

Spinifex Pharmaceuticals Appoints Neuroscience Expert Dr Ronald Marcus as Chief Medical Officer

Spinifex Pharmaceuticals, a pain drug development company, today announces that it has appointed Dr Ronald Marcus as Chief Medical Officer. Dr...

May 27, 2014, 04:00 ET

Spinifex Pharmaceuticals Strengthens Scientific Advisory Board (SAB) with Experts in Chronic Pain

Expanded SAB will oversee development of EMA401, Company's lead program for treating chronic pain   Spinifex Pharmaceuticals, a pain drug...

Apr 10, 2014, 19:01 ET

Spinifex Pharmaceuticals Raises US$45m in Series C Financing

- Syndicate includes Novo A/S and Canaan Partners alongside existing investors - New funds to drive the development of Spinifex's lead...

Feb 05, 2014, 03:00 ET

Spinifex Pharmaceuticals' Phase 2 Results Published in The Lancet Show EMA401 to be Effective in Reducing Pain in Postherpetic Neuralgia

- Phase 2 trial met its primary endpoint, reduced pain in postherpetic neuralgia (PHN) versus placebo - Significant patient response to...

Oct 18, 2013, 04:00 ET

Spinifex Pharmaceuticals' EMA401 Named One of the Top Ten Neuroscience Projects to Watch

Company to present at Elsevier Business Intelligence's 2013 Therapeutic Area Partnerships Spinifex Pharmaceuticals, an Australian pain drug...

Mar 27, 2013, 07:32 ET

Spinifex Receives $1.5m in R&D Tax Incentive for Research Activities Related to the Discovery of Treatments for Pain

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces it has received an approximately AUS$1.5 million R&D...

Dec 10, 2012, 04:00 ET

Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces that the first patients have been treated in its Phase 2...

Aug 28, 2012, 02:00 ET

Spinifex Announces Positive Phase 2 Results for EMA401 in Postherpetic Neuralgia

Trial Meets Primary Endpoint: Reduction in Pain Spinifex Pharmaceuticals, an Australian pain drug development company, today announces positive...

Dec 08, 2011, 05:13 ET

Spinifex Appoints Declan Doogan as Non-Executive Chairman

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces the appointment of Dr Declan Doogan as Non-Executive...

Sep 12, 2011, 04:00 ET

New Data on EMA401 in Model of Diabetic Neuropathy Presented at 21st Annual NEURODIAB Meeting

  EMA401 Shown to Improve Nerve and Neurovascular Function Spinifex Pharmaceuticals, an Australian pain drug development company, today...

Aug 23, 2011, 04:00 ET

Spinifex Closes AU$18.25M(~US$19M) Expanded Series B Round

Additional Funds to Broaden Phase  2 Program for New Pain Drug - AU$6.25M (~US$6.5M) investment by GBS...